|By PR Newswire||
|March 27, 2014 11:40 AM EDT||
DUBLIN, Mar. 27, 2014 /PRNewswire/ --
Research and Markets
) has announced the addition of the
report to their offering.
Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter!
Inflectra is a biosimilar of Johnson & Johnson's Remicade, which is approved for RA, Crohn's disease and several other conditions and had $2 billion in sales in Europe last year. This approval has further increase the optimism of companies developing and marketing biosimilars and the wait for the launch of others in queue Rituxan, Herecptin, Enbrel etc may not be too long. These three drugs alone had worldwide sales of -$21b in 2012.
Commercial success of biosimilars will be depend both on affordability and accessibility assuming that the copy molecule is at par on efficacy, safety and similarity with the branded product. Uptake and marketing strategy of Remicade biosimilar will be closely watched by investors as well as companies developing/marketing Biosimilars. In this report, we have analyzed the market opportunity of rituximab biosimilar.
Key Topics Covered:
1. Executive Summary
2.Ex-US Experience of Biosimilar launch
3.Introduction - Rituxan/ MabThera (rituximab)
4.Opportunities and Threats for Rituximab Biosimilar
5.A brief on Companies Developing Rituximab Biosimilar
6.Our view on Risk/Reward profile of developing Rituximab Biosimilar
7.About the biosimilar spaceDifferent Technologies Deployed By Biosimilar Players
- Biogen Idec
- Dr Reddys
- Type II
- life cycle management
- monoclonal antibody
For more information visit http://www.researchandmarkets.com/research/rwdz5w/therapy_clas
Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
May. 4, 2016 07:00 PM EDT Reads: 1,262
May. 4, 2016 07:00 PM EDT Reads: 1,301
May. 4, 2016 05:30 PM EDT Reads: 1,370
May. 4, 2016 05:15 PM EDT Reads: 367
May. 4, 2016 05:00 PM EDT Reads: 1,315
May. 4, 2016 04:30 PM EDT Reads: 821
May. 4, 2016 03:30 PM EDT Reads: 620
May. 4, 2016 03:00 PM EDT Reads: 1,046
May. 4, 2016 03:00 PM EDT Reads: 1,170
May. 4, 2016 02:00 PM EDT Reads: 1,220
May. 4, 2016 02:00 PM EDT Reads: 1,275
May. 4, 2016 01:45 PM EDT Reads: 1,110
May. 4, 2016 01:45 PM EDT Reads: 1,335
May. 4, 2016 01:00 PM EDT Reads: 1,425
We're entering the post-smartphone era, where wearable gadgets from watches and fitness bands to glasses and health aids will power the next technological revolution. With mass adoption of wearable devices comes a new data ecosystem that must be protected. Wearables open new pathways that facilitate the tracking, sharing and storing of consumers’ personal health, location and daily activity data. Consumers have some idea of the data these devices capture, but most don’t realize how revealing and...
May. 4, 2016 12:45 PM EDT Reads: 613